A US-based key opinion leader providers insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for triple- negative breast cancer. Diagnostic testing, biomarker disease segmentation, and unmet needs are also discussed.
Key pipeline assets highlighted include:
- balixafortide
- keytruda
- sacituzumab govitecan
- trastuzumab deruxtecan
- veliparib
Table of Contents
- Highlights
- About the Author
- Disclaimer
- Q&A
